^[1] Le Berre C et al. Ulcerative colitis. The Lancet,2023 ; 402(10401) : 571-584.

^[2] Peyrin-Biroulet L et al. Selecting Therapeutic Targets in IBD (STRIDE) : Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep ; 110(9): 1324-38

^[3] Turner D et al. STRIDE-II : An Updateon the Selecting Therapeutic Targets in IBD (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD) : Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021 ; 160: 1570-83.

^[4] Rubin DT et al. International Perspectives on Management of IBD : Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis 2021 ; 27 : 1942-53.

^[5] Ott C et Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013 ; 10 : 585-95.

^[6] Guidance for Industry: patient-reported outcome measures: use in medical product development to support labelling claims Food and Drug Administration. 2009. Published Online First : 2009. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf

^[7] Williet N et al. Patient-reported Outcomes in a French Nationwide Survey of IBD Patients. J Crohns Colitis2017 ; 11 : 165-74.

^[8] Caron B et al. Identifying, Understanding, and Managing Fecal Urgency in IBD. Clinical Gastroenterology and Hepatology 2023 ; 21 : 1403-1413.e27.

^[9] Casellas F et al. Patient preferences for IBD treatment objectives. Dig Liver Dis 2017; 49 : 152-6.

^[10] Nachury M et al. Patients’ real-world experience with IBD: A cross-sectional survey in tertiary care centres from the GETAID group. Dig Liver Dis 2021 ; 53 : 434-41.

^[11] Buisson A et al. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with IBD. Inflamm Bowel Dis 2017 ; 23 : 1425-33.

^[12] Maréchal C et al. Compliance with the faecal calprotectin test in patients with IBD. United European Gastroenterol J 2017 ; 5 : 702-7.

^[13] Rohatinsky N et al. An Exploratory Study of Health-related Quality of Life and Care Experiences in Older Adults with IBD. Journal of the Canadian Association of Gastroenterology 2023; 6 : 116-24.

^[14] Buisson A, Nachury M. Comment mieux annoncer le diagnostic d’une maladie inflammatoire chronique de l’intestin ? HGOD 2023 ; 30 : 597-604

^[15] Fiorino G et al. ‘Quality of Care’ Standards in IBD : A Systematic Review. Journal of Crohn’s and Colitis 2019 ; 13 : 127-37.

^[16] Sudhakar P et al. Holistic healthcare in IBD : time for patient-centric approaches ? Gut 2023 ; 72 : 192-204.

^[17] Baumgart DC et al. Newer Biologic and Small-Molecule Thera- pies for IBD. N Engl J Med 2021 ; 385: 1302-15.